TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37437885

Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 37437986

Group type: EXPERIMENTAL
Intervention: Phytocompounds targeting mitochondria
Number of subjects: 0
Study: 37438058

Group type: EXPERIMENTAL
Intervention: Training in good clinical practice and support for patient recruitment, data collection, and documentation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus groups with researchers, semi-structured interviews with general practitioners, and questionnaires for patients.
Number of subjects: 0
Study: 37438060

Group type: EXPERIMENTAL
Intervention: Automated pupillometry (Neurological Pupil Index; NPi-200, Neuroptics) assessed two times per day for 7 days
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Automated pupillometry parameters
Number of subjects: 213
Study: 37438064

Group type: EXPERIMENTAL
Intervention: Continuum of care for maternal health service utilisation
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Discussion about family planning with husband
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Possession of electronic devices
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Unmet need for family planning
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Polygamous marriage
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Attitude towards family planning
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Subjective norm
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Perceived control over family planning
Number of subjects: 891
Study: 37438067

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (one-time male-specific counseling + facility navigation only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (immediate outside-facility ART initiation + male-specific counselling + facility navigation for follow-up ART visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped intervention (increasing intensity over time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 37438068

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) level of 7 cmH2O during spontaneous breathing trial (SBT)
Number of subjects: 0
Study: 37438071

Group type: EXPERIMENTAL
Intervention: Patterned sensory enhancement (PSE) training for 21 days
Number of subjects: 138

Group type: COMPARATOR
Intervention: No patterned sensory enhancement (no-PSE) training for 21 days
Number of subjects: 138
Study: 37438187

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMO-supplemented formula milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfeeding encouragement
Number of subjects: 0
Study: 37438197

Group type: EXPERIMENTAL
Intervention: ivacaftor therapy
Number of subjects: 15
Study: 37438493

Group type: EXPERIMENTAL
Intervention: Oral prolonged-release tablet (1.9 mg melatonin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Immediate-release sublingual spray (1 mg melatonin)
Number of subjects: 14
Study: 37438520

Group type: EXPERIMENTAL
Intervention: Planetary health innovation
Number of subjects: 0
Study: 37438722

Group type: EXPERIMENTAL
Intervention: Approach Avoidance Training (AAT) for 6 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham training for 6 weeks
Number of subjects: 136
Study: 37438734

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2627

Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 ratio increase
Number of subjects: 2627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2627
Study: 37438741

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle (EV) mtDNA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole blood (WB) mtDNA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tumor tissues
Number of subjects: 16
Study: 37438759

Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; average of 6.2 days of intervention (14.8 min daily).
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; adjusted hazard ratio 2.35; 95% CI 1.38-4.01.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; adjusted odds ratio 0.28; 95% CI 0.12-0.65.
Number of subjects: 145
Study: 37438776

Group type: EXPERIMENTAL
Intervention: Nudge intervention comprising three SMS text message reminders with links to short educational videos and vaccine safety information.
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 2076
Study: 37438853

Group type: EXPERIMENTAL
Intervention: Intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 37439084

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with radiotherapy (n=18)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy without radiotherapy (n=5)
Number of subjects: 23
Study: 37439181

Group type: EXPERIMENTAL
Intervention: xevinapant plus chemoradiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: liquid placebo plus chemoradiotherapy
Number of subjects: 50
Study: 37439219

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase followed by coronary angiography and PCI (if indicated)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase and Primary PCI
Number of subjects: 604
Study: 37439259

Group type: EXPERIMENTAL
Intervention: Noninvasive In Vivo Thrombus Imaging
Number of subjects: 11
Study: 37439343

Group type: EXPERIMENTAL
Intervention: Tenalisib 800 mg twice daily orally and romidepsin 14 mg/m2 intravenous on days 1, 8, and 15 in 28-day cycles
Number of subjects: 33
Study: 37439365

Group type: EXPERIMENTAL
Intervention: Tonic motor activation (TOMAC) for 24 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham (control) for 24 weeks
Number of subjects: 103
Study: 37439374

Group type: EXPERIMENTAL
Intervention: Clinically diagnosed MGUS
Number of subjects: 3352

Group type: COMPARATOR
Intervention: Screened MGUS
Number of subjects: 3352
Study: 37439373

Group type: EXPERIMENTAL
Intervention: Recent transfusion events
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Metabolite levels (S1P, L-arginine, kynurenine, acyl-carnitines, bile acids)
Number of subjects: 596
Study: 37439451

Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case one
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case two
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case three
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Physiotherapist characteristics (younger colleagues and those holding a Ph.D.)
Number of subjects: 47
Study: 37439519

Group type: EXPERIMENTAL
Intervention: EUS-LB
Number of subjects: 90

Group type: COMPARATOR
Intervention: Percutaneous LB
Number of subjects: 90
Study: 37439564

Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE) research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient involvement in RWE studies
Number of subjects: 0
Study: 37439701

Group type: EXPERIMENTAL
Intervention: Heterologous SCB-2019 booster (full or half dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Homologous CoronaVac booster
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Full-dose SCB-2019 booster
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Half-dose SCB-2019 booster
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SCB-2019 booster (full or half dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CoronaVac booster
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heterologous SCB-2019 booster
Number of subjects: 30
Study: 37439961

Group type: EXPERIMENTAL
Intervention: Esketamine + SOC
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 451
Study: 37440099

Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program - Neurofibromatosis (3RP-NF)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Health Education Control (HEP-NF)
Number of subjects: 228
Study: 37440156

Group type: EXPERIMENTAL
Intervention: Behaviorally based intervention
Number of subjects: 128
Study: 37440205

Group type: EXPERIMENTAL
Intervention: Dynamic compliance-guided PEEP (PEEP with highest dynamic compliance plus 2 cm H2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEEP of 8 cm H2O
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic compliance-guided PEEP
Number of subjects: 40
Study: 37440213

Group type: EXPERIMENTAL
Intervention: Atropine, 0.01%, eye drops
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 37440217

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg/d for those with body weight <77 kg and/or platelet count <150 ×103/μL; 300 mg/d otherwise)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 37440232

Group type: EXPERIMENTAL
Intervention: Internet-delivered emotion regulation therapy plus treatment as usual
Number of subjects: 166

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 166
Study: 37440230

Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention (6 lay health worker-led weekly problem-solving therapy sessions)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Enhanced standard care (control group)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention
Number of subjects: 516
Study: 37440239

Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine, cyclophosphamide, and capecitabine (VEX)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Weekly intravenous paclitaxel
Number of subjects: 140
Study: 37440307

Group type: EXPERIMENTAL
Intervention: AI-based platform for TCR selection; observational study protocol; patient samples collected, including primary tumor tissue and peripheral blood samples.
Number of subjects: 100
Study: 37440425

Group type: EXPERIMENTAL
Intervention: New learning curve-based simulator training (individualized training time based on performance)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference fixed training time simulator training (1 hour)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: New learning curve-based simulator training
Number of subjects: 32
Study: 37440465

Group type: EXPERIMENTAL
Intervention: Knowledge of home pregnancy test kits
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Use of home pregnancy test kits
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Barriers to purchasing home pregnancy test kits
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Demographics of women with knowledge of home pregnancy test kits
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Characteristics of women lacking support from partners
Number of subjects: 1008
Study: 37440779

Group type: EXPERIMENTAL
Intervention: Tegoprazan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study: 37440977

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care exercise-based rehabilitation
Number of subjects: 81
Study: 37441067

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program for 3 months and use of a pedometer watch for one year
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no APA program and no pedometer watch)
Number of subjects: 40
Study: 37441104

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 147
Study: 37441145

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using pressure pain threshold strong response acupoints (PSA) and temperature strong response acupoints (TSA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intradermal acupuncture (IA) treatment using clinical common acupoint (CCA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using TSA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using PSA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment
Number of subjects: 120
Study: 37441479

Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023), an oral, first-in-class, highly potent, proximal alternative pathway inhibitor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Number of subjects: 0
Study: 37441500

Group type: EXPERIMENTAL
Intervention: 10 L of oxygen per minute in a tight-fitting simple facemask until delivery
Number of subjects: 140

Group type: COMPARATOR
Intervention: Room air only
Number of subjects: 140
Study: 37441541

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 37441544

Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiotherapy (WBRT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Observation after local treatment
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Not having neurosurgery at baseline
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Having 2-3 brain metastases
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 139
Study: 37441546

Group type: EXPERIMENTAL
Intervention: Cicaderma® (Arm A)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Preventive treatment according to investigator preference (Arm B)
Number of subjects: 258
Study: 37441683

Group type: EXPERIMENTAL
Intervention: High protein/dairy nutrition and walking exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37442152

Group type: COMPARATOR
Intervention: Control group (nucleos(t)ide analogues plus placebo)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 40 mg group
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 100 mg group
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 200 mg group
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Triple group (JNJ-6379 250 mg plus JNJ-3989 100 mg plus nucleos(t)ide analogues)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: JNJ-6379 dual group
Number of subjects: 470
Study: 37442271

Group type: EXPERIMENTAL
Intervention: Lower atmospheric pressure
Number of subjects: 9913

Group type: EXPERIMENTAL
Intervention: Higher humidity
Number of subjects: 9913

Group type: EXPERIMENTAL
Intervention: Lower temperatures
Number of subjects: 9913
Study: 37442349

Group type: EXPERIMENTAL
Intervention: Psychological intervention (details not specified)
Number of subjects: 156

Group type: COMPARATOR
Intervention: HSCT population
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 156
Study: 37442430

Group type: EXPERIMENTAL
Intervention: 40 Gy in 5 fractions (DL1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 42.5 Gy in 5 fractions (DL2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 fractions (DL3)
Number of subjects: 8
Study: 37442585

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nails
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Unreamed intramedullary nails
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Reamed and unreamed nails (both groups)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Patients whose first reoperation was for infection
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Patients requiring multiple procedures for nonunion or bone loss
Number of subjects: 1226
Study: 37442656

Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin extended release (XR) (5/500 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) and metformin XR (1000 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dapagliflozin/metformin FDC
Number of subjects: 80

Group type: COMPARATOR
Intervention: IC tablets (dapagliflozin [5 mg] and metformin XR [500 mg])
Number of subjects: 80
Study: 37442748

Group type: EXPERIMENTAL
Intervention: Sugemalimab 1200 mg every 3 weeks for up to 12 months
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to 12 months
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Sugemalimab 1200 mg
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 37442844

Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation (INTELLiVENT-Adaptive Support Ventilation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional pressure controlled ventilation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation (INTELLiVENT-ASV)
Number of subjects: 13
Study: 37442868

Group type: EXPERIMENTAL
Intervention: Implementation Studio training and consultation program
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CHE-delivered EBIs
Number of subjects: 13
Study: 37442883

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (25μg every 4 hours, maximum 5 doses)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Oxytocin infusion (according to hospital protocol)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 173

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 173
Study: 37442917

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 91
Study: 37442955

Group type: EXPERIMENTAL
Intervention: Parent and child ADHD screening protocol during annual well-child visits in pediatric primary care clinics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stakeholder group meetings to gather feedback on implementation challenges.
Number of subjects: 0
Study: 37442999

Group type: EXPERIMENTAL
Intervention: Culturally tailored model of Family Psychoeducation (KUPAA)
Number of subjects: 66
Study: 37443016

Group type: EXPERIMENTAL
Intervention: Semi-upright position (30 to 45 degrees incline)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (zero degrees from horizontal)
Number of subjects: 35
Study: 37443044

Group type: EXPERIMENTAL
Intervention: Multicomponent strategy including mHealth outreach, care coordination, and community advisory boards
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multicomponent strategy
Number of subjects: 300
Study: 37443047

Group type: EXPERIMENTAL
Intervention: Salivary rapid nucleic acid test (Abbott ID NOW STREP A2)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Pharyngeal rapid antigen detection test (EXACTO PRO STREPTATEST)
Number of subjects: 800
Study: 37443061

Group type: EXPERIMENTAL
Intervention: Quantitative light induced fluorescence (QLF) technology
Number of subjects: 0
Study: 37443083

Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's Lactate (RL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 52
Study: 37443130

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 414
Study: 37443348

Group type: EXPERIMENTAL
Intervention: Pelareorep and pembrolizumab (iv pelareorep induction with pembrolizumab every 21-days)
Number of subjects: 12
Study: 37443414

Group type: EXPERIMENTAL
Intervention: Nurse navigation program-based nursing care (three home visits, four phone calls, five text messages)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard hospital care during delivery and postpartum period
Number of subjects: 64
Study: 37443452

Group type: EXPERIMENTAL
Intervention: SCH-TPOAb [-] group (levothyroxine treatment)
Number of subjects: 171

Group type: COMPARATOR
Intervention: SCH-TPOAb [+] group (control)
Number of subjects: 171
Study: 37443809

Group type: EXPERIMENTAL
Intervention: Increased CRP protein levels of ≥5 mg/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variant rs1130864
Number of subjects: 0
Study: 37444406

Group type: EXPERIMENTAL
Intervention: Current MDS treatments
Number of subjects: 75
Study: 37444551

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg, po BID)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Interruption of Sorafenib treatment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Maintenance of Sorafenib treatment
Number of subjects: 151
Study: 37444634

Group type: EXPERIMENTAL
Intervention: High-dose radiation treatment for brain regions with Cho/NAA ≥ 2x normal
Number of subjects: 0
Study: 37444757

Group type: EXPERIMENTAL
Intervention: Fertility-sparing surgery
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Comprehensive surgical staging
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: High levels of Ca-125
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serous BOT diagnosis
Number of subjects: 86
Study: 37444782

Group type: EXPERIMENTAL
Intervention: TEPOH (multicomponent intervention including an introductory session, three educational sessions, and a debriefing session)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 81
Study: 37445292

Group type: EXPERIMENTAL
Intervention: Essential amino acid mixture with tricarboxylic acid cycle intermediates (PD-E07), N = 10
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CTR), N = 10
Number of subjects: 40
Study: 37446173

Group type: EXPERIMENTAL
Intervention: Nitisinone treatment
Number of subjects: 0
Study: 37448202

Group type: EXPERIMENTAL
Intervention: Nutrition + exercise intervention (bi-weekly nutrition counselling, high dairy protein diet, walking goal of 10,000 steps/day, plus usual prenatal care)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual prenatal care (UPC) alone
Number of subjects: 100
Study: 37448353

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (1.0 to 1.5 g orally)
Number of subjects: 0
Study: 37448694

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg daily for six months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 37448803

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14